This forum will include discussions and updates from CCDIE and NMPA leadership on many important topics including the implementation of the revision of drug law and updated regulations, ICH implementation, and advanced therapy.
Learning Objectives
Discuss updates from CCDIE and NMPA leadership.
Chair
Ling Su, PhD
Speaker
New Progress of New Drug Evaluation Fan Zhang, MS
Pre-Approval Inspection in China: Its Evolution and Key Points of Evaluation Principles Yi Cao, MS
Pre-Approval Inspection in China: Its Evolution and Key Points of Evaluation Principles Tiewei Zhai
Research Fellow, Shenyang Pharmaceutical University, Yeehong Business School, China
Dr. Ling Su is a Research Fellow in Shengyang Pharmaceutical University Yeehong Business School and a Venture Partner in Lilly Asia Ventures (LAV). He has 30 years of experience in drug regulatory and development. He had worked in various R&D management positions in the pharma industry... Read More →
Deputy Division Director, Div 4, Center for Food and Drug Inspection (CFDI)
Mr. Cao is mainly responsible for pre-approval inspection and overseas GMP inspection. Before joined in CFDI, he worked at Beijing Institute for Drug Control for 5 years
